Ciclesonide Market Analysis & Forecast: 2026-2033

Ciclesonide Market Size and Share Analysis - Growth Trends and Forecast (2026 - 2033)

The global Ciclesonide Market is anticipated to grow at a CAGR of 1.9% with USD 658.1 Mn share in 2026 and is expected to reach USD 750.8 Mn in 2033. Increasing prevalence of asthma and allergic rhinitis, rising demand for inhaled corticosteroids, growing respiratory disease burden, and improved availability of advanced pulmonary therapies are supporting market growth worldwide. Allergic rhinitis affects 10–40% of the population, making it one of the most prevalent allergic conditions worldwide, with a rising global prevalence.

Key Takeaways from the Global Ciclesonide Market Report

• In terms of indication, the asthma segment will capture the leading position with a share of 68.4% in 2026 because of the high prevalence of respiratory diseases across the globe and increased use of inhaled corticosteroids. As per WHO
• The aerosol segment is projected to dominate the market share with 61.2% in 2026 because of greater prescription rates for inhalation-based asthma treatments as well as higher efficiency of pulmonary drug delivery systems. Increasing inclination towards using metered-dose inhalers and maintenance inhalation for asthma treatments drives segment growth.
• North America is projected to account for the largest share of the ciclesonide market at 39.7% in 2026 due to the higher prevalence of asthma and allergic rhinitis, good healthcare facilities, and high acceptance of the inhalation corticosteroids medication. The Centers for Disease Control and Prevention (CDC) estimates that about 28 million people in the United States suffer from asthma, indicating high regional demand for drugs treating respiratory disorders, such as ciclesonide.

Rising Prevalence of Respiratory Disorders is Driving Growth of the Ciclesonide Market

With an increasing global prevalence of asthma and allergic rhinitis, the need for inhaled corticosteroids like ciclesonide has grown. Exposure to environmental pollutants, allergies, cigarette smoke, and respiratory infections has considerably expanded the patient population that requires long-term anti-inflammatory treatment of the respiratory system. Ciclesonide is widely preferred because of its targeted pulmonary actionand higher compliance rates in patients with chronic respiratory diseases.

According to the Global Initiative for Asthma (GINA) Reports, asthma affects more than 300 million individuals globally and is considered one of the most prevalent chronic respiratory illnesses in the world. The rising number of affected individuals from both children and adults is driving up the demand for inhalers like ciclesonide.

Increasing Adoption of Inhalation-Based Therapies is Supporting Market Expansion

The increasing adoption of inhalation-based drug delivery has significantly contributed to the global use of ciclesonide therapies. Inhaling corticosteroids provide quick action, better targeting of lungs, lesser risk of entering into the bloodstream, and improved efficacy compared to traditional oral methods. Healthcare professionals increasingly recommend inhalation therapies for asthma and allergy management because of their targeted action and improved safety profile.

As reported by the American Lung Association's Asthma Trends & Burden Report, asthma continues to be one of the most common illnesses amongst children and adults in the U.S., resulting in millions of visits to doctors every year. The growing burden of respiratory disease is increasing demand for long-term maintenance inhaler therapies.

Current Events and Their Impact on the Ciclesonide Market

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Segmental Insights 

To learn more about this report, Request Free Sample

Why is Asthma Acquiring the Largest Market Share in the Ciclesonide Market?

Asthma is expected to occupy the largest market share for ciclesonide globally, comprising about 68.4% of the overall value of the market in 2026. The rising prevalence of chronic respiratory ailments across the globe and increasing use of inhaled steroids to manage asthma have led to an increased demand for ciclesonide in asthma management. Increasing exposure to air pollution, cigarette smoking, allergens, and respiratory diseases has contributed to the increase in the patient population suffering from respiratory ailments.

In May 2025, GSK Official Respiratory Medicine Advancements at ATS 2025 announced new clinical data presentations for its respiratory portfolio, including asthma biologics and inhalation therapies.

Why is Aerosol the Dominating Dosage Form Segment in the Ciclesonide Market? 

To learn more about this report, Request Free Sample

The aerosol segment is predicted to hold the largest market share of 61.2% in 2026, owing to the enhanced efficacy of pulmonary delivery of drugs, fast mode of action, and extensive application of the category in the management of asthma conditions. Aerosol inhalation therapies enable targeted delivery of corticosteroids directly into the lungs.

The growing demand for metered dose inhalers, improvements in aerosols, and an increased uptake of maintenance inhalation therapy in chronic asthmatic patients are fueling the growth of the market segment. Moreover, aerosols provide improved dose uniformity and ease of administration, and thus are greatly favored by healthcare professionals and patients.

In May 2025, Lupin HFO Technology in Inhalers announced collaboration plans with Honeywell to develop next-generation pressurized metered-dose inhalers (pMDIs) using Solstice Air propellant technology.

Ciclesonide Market Trends

• Increasing use of inhalation corticosteroids for asthma and allergic rhinitis is contributing positively to the management of diseases and increasing patient compliance around the world. There is an increasing preference for metered dose inhalers and aerosols, which deliver the medication directly into the lungs.
• Increasing prevalence of respiratory disorders is accelerating demand for maintenance inhalation therapies worldwide. According to the Global Initiative for Asthma (GINA) Reports, asthma affects more than 300 million people globally, significantly driving long-term demand for inhaled corticosteroids such as ciclesonide.
• Growing pollution and deteriorating air quality have been identified as some of the reasons behind the increase in respiratory ailments and allergies. As per information provided in WHO Air Pollution Factsheet, around 99% of people around the world breathe polluted air which exceeds the guidelines set by WHO.
• Drug companies are now giving more emphasis to developing environmentally friendly aerosol inhalers as well as propellants that have low global warming potential. Latest developments in inhalers have significantly improved drug delivery accuracy, portability, and compliance in asthma patients.
• Increased healthcare awareness and greater access to treatments related to respiration in developing countries are helping drive market growth. Increased diagnosis cases of asthma and allergic rhinitis coupled with better healthcare infrastructure in Asia Pacific and Latin America are driving the demand for Ciclesonide treatments worldwide.

Regional Insights 

To learn more about this report, Request Free Sample

North America Dominates the Ciclesonide Market Owing to Rising Prevalence of Respiratory Disorders

North America is anticipated to hold a 39.7% market share in 2026 owing to a high prevalence rate of asthma and allergic rhinitis and robust health care infrastructure. Over 3 million Canadians aged 12 years and older (8.5% of the population) have diagnosed asthma, which causes approximately 146,000 annual emergency department visits and is a major contributor to hospitalizations and school absenteeism. The increased prevalence of inhaled corticosteroid drugs coupled with the presence of key pharmaceutical players is further boosting market growth in the region.

Asia Pacific Ciclesonide Market Trends

The Asia Pacific region is expected to grow at the highest rate, growing at around 2.5% CAGR from 2026 to 2033. The drivers for this growth include increased incidences of respiratory diseases, rising healthcare expenditure, deteriorating quality of urban air, and increased accessibility to respiratory drugs in emerging countries like China and India. Chronic respiratory diseases affect nearly 545 million people globally and cause more than 4.2 million deaths each year. India bears a substantial burden, with approximately 55.23 million COPD cases and 43% of worldwide asthma-related deaths.

In addition, pharmaceutical companies across Asia Pacific are expanding respiratory drug manufacturing and inhaler technology capabilities. In May 2025, Lupin Respiratory Inhaler Innovation Partnership announced plans to integrate next-generation eco-friendly propellant technology into respiratory aerosol inhalers.

Rising Prevalence of Asthma is Accelerating the Ciclesonide Market Demand in the United States

The United States ciclesonide market is experiencing stable growth because of the rising incidence of asthmatic conditions and allergic rhinitis, high adoption of inhaled corticosteroid treatment regimens, and the presence of well-developed health care infrastructure that enables the management of respiratory diseases. Growing pollution, smoking, and respiratory allergies are further driving the use of inhalers. In United States, 8.8% of adults (47.7 million people) continue to use tobacco products, and smoking remains a leading cause of preventable death.

In October 2025, Amneal Pharmaceuticals FDA Tentative Approval for Beclomethasone Dipropionate HFA Inhalation Aerosol announced that the U.S. FDA granted tentative approval for the company’s beclomethasone dipropionate HFA inhalation aerosol, a generic equivalent of QVAR®.

Japan Ciclesonide Market Trends

The Japan ciclesonide market is projected to grow steadily during the forecast period owing to the country’s aging population, rising prevalence of chronic respiratory diseases, and increasing healthcare expenditure on respiratory care. Japan remains one of the world’s most aged societies, which significantly increases susceptibility to asthma, chronic obstructive pulmonary disease (COPD), and allergy-related respiratory conditions.

In December 2025, Regeneron Official Dupixent Approved in Japan for Pediatric Asthma announced that Japan’s Ministry of Health, Labour and Welfare approved Dupixent (dupilumab) for children aged 6–11 years with severe bronchial asthma.

Who are the Major Companies in Ciclesonide Industry

Some of the major key players in Ciclesonide are AstraZeneca Plc, Cipla Limited, Sun Pharmaceutical Industries Ltd., and Apotex Inc.

Key News

• In May 2025, AstraZeneca announced positive Phase III trial results for Breztri Aerosphere in asthma treatment. The company reported significant improvements in lung function in uncontrolled asthma patients, strengthening AstraZeneca’s respiratory inhalation therapy portfolio.
• In October 2025, Cipla announced expansion of its flagship respiratory initiative “Breathefree” into the UAE market to improve awareness and management of asthma and allergic respiratory conditions across the Middle East.

Market Report Scope 

Analyst Opinion

• The demand for ciclesonide is largely influenced by the rising prevalence of respiratory ailments worldwide as opposed to current healthcare developments.
• Respiratory treatments via inhalation are still becoming more clinically preferred owing to their selective pulmonary action and minimal side effects. Corticosteroids in aerosol form like ciclesonide have gained preference for chronic asthma and rhinitis because of better patient compliance and improved results.
• Environmental pollution remains a major catalyst for respiratory therapeutics demand globally. The World Health Organization (WHO) Air Pollution Factsheet states that nearly 99% of the world’s population breathes air exceeding WHO guideline limits, significantly contributing to rising respiratory illnesses and allergy-related conditions.
• The development of technological advancements in inhaler technology and environmental inhalers with reduced global warming potential is likely to define the future of respiration management. The pharmaceutical industry has seen more investments being directed towards developing environmental inhalers and innovative aerosol delivery technologies in recent times.
• Increased growth in aging population across the world will act as another positive driver for the market, due to the fact that seniors are more vulnerable to chronic respiratory conditions such as asthma, COPD, and allergic airways disease.

Market Segmentation

• By Indication (Revenue, USD Mn, 2021-2033)
  • Allergy Rhinitis
  • Asthma
• By Dosage Form (Revenue, USD Mn, 2021-2033)
  • Aerosol
  • Nasal Spray
• By Region (Revenue, USD Mn, 2021-2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • Central Africa
    • North Africa

Sources

Primary Research Interviews

• Respiratory physicians and pulmonologists
• Asthma and allergy specialists
• Hospital pharmacy procurement managers
• Respiratory therapy clinicians
• Inhalation drug distributors and suppliers
• Key opinion leaders (KOLs) in respiratory medicine
• Healthcare policymakers and reimbursement experts

Databases

• World Health Organization (WHO)
• Centers for Disease Control and Prevention (CDC)
• National Institutes of Health (NIH)
• Global Initiative for Asthma (GINA)
• Organisation for Economic Co-operation and Development (OECD)

Magazines

• Respiratory Therapy Magazine
• PharmaTimes
• Drug Topics

Journals

• The Lancet Respiratory Medicine
• Journal of Asthma
• European Respiratory Journal
• American Journal of Respiratory and Critical Care Medicine

Newspapers

• The New York Times
• The Guardian
• The Wall Street Journal

Associations

• American Thoracic Society (ATS)
• European Respiratory Society (ERS)
• American Academy of Allergy, Asthma & Immunology (AAAAI)
• Global Initiative for Asthma (GINA)

Public Domain Sources

• Company Annual Reports and Investor Presentations
• Government Health Ministry Publications
• Clinical Trial Registries such as ClinicalTrials.gov
• FDA Drug Approval Databases and Regulatory Filings

Proprietary Elements

• CMI Data Analytics Tool
• Proprietary CMI Existing Repository of Information for Last 10 Years